Navigoe Wealth Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Navigoe Wealth Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	+1	New	+$48	﹤0.01%	1086

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Navigoe Wealth Management's SUPN Position: Q2 2026 in Review

Navigoe Wealth Management opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 1 share worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1086 among its holdings.

332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Navigoe Wealth Management held 1 share of Supernus Pharmaceuticals worth $0 as of Q2 2026.
Supernus Pharmaceuticals was a new Navigoe Wealth Management position in Q2 2026.
Supernus Pharmaceuticals made up ﹤0.01% of Navigoe Wealth Management's portfolio in Q2 2026, its #1086 holding.
332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Navigoe Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.